While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals
Sep 15, 2020
AstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UK After receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and ...
Read More
Moderna’s COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates
Aug 27, 2020
Moderna’s COVID-19 vaccine triggers an immune response in older adults Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. I...
Read More
Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis
Aug 26, 2020
Novartis’s Spartalizumab Combo Fails To Meet The Primary Goal In The Melanoma Trial Novartis recently declared the results of its Phase III COMBI-I trial evaluating...
Read More
Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug
Aug 13, 2020
Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The ca...
Read More
FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem
Aug 11, 2020
Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Gene...
Read More
Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target
Aug 6, 2020
Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to ...
Read More
MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results
Aug 4, 2020
MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated ap...
Read More
Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack
Jul 23, 2020
Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D effor...
Read More
AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership
Jul 21, 2020
AstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222 In a frenzied race to find a global cure for COVID-19, several pharma pla...
Read More
Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update
Jul 16, 2020
Orchard licenses the gene therapy technology from GlaxoSmithKline Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for i...
Read More
Merck, Dewpoint’s HIV Pipeline; Pfizer, BioNTech ‘s COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer
Jul 14, 2020
Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates Dewpoint was launched last year to explore and uncover novel mechanisms to treat one of th...
Read More
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies
Jul 7, 2020
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for pr...
Read More
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M
Jul 6, 2020
Regeneron recognizes new combos to boost I-O drug Libtayo’s cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patien...
Read More
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result
Jul 6, 2020
Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases T...
Read More
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M
Jul 6, 2020
Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and...
Read More
